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The	  recent	  development	  of	  biohybrid	  catalytic	  systems	  has	  allowed	  synthetic	  chemists	  to	  reach	  high	  levels	  of	  selectivity	  on	  
a	  wide	  variety	  of	  valuable	   synthetic	   transformations.	   In	   this	   context,	  DNA-­‐based	  catalysts	  have	  emerged	  as	  particularly	  
appealing	  tools.	  Interestingly,	  while	  long	  RNA	  sequences	  (ribozymes)	  are	  known	  to	  catalyse	  specific	  biochemical	  reactions	  
with	   remarkable	   efficiencies,	   RNA-­‐based	   catalysts	   in-­‐volving	   a	   catalytically	   active	   metal	   complex	   interacting	   in	   a	   non-­‐
covalent	  fashion	  with	  short	  sequences	  have	  never	  been	  evaluated	  to	  date.	  We	  report	  here	  our	  results,	  which	  have	  led	  to	  
the	  first	  example	  involving	  a	  short	  RNA-­‐based	  catalyst.	  
Ten	   years	   ago,	   Roelfes	   and	   Feringa	   published	   the	   first	   article	   pertaining	   to	   the	   use	   of	   double-­‐stranded	   DNA	   (dsDNA)	   as	   a	  
stereochemical	   control	   element	   in	   a	   Diels-­‐Alder	   reaction.1	   Distinct	   from	   artificial	   DNAzyme	   approaches	   obtained	   through	   the	  
systematic	  evolution	  of	  ligands	  by	  exponential	  enrichment	  processes	  (SELEX),2	  this	  landmark	  was	  received	  with	  a	  lot	  of	  enthusiasm	  
from	   scientists	   working	   in	   the	   field	   of	   asymmetric	   artificial	   biohybrid-­‐mediated	   catalysis	   who,	   along	   with	   the	   initial	   authors,	  
extended	   the	   concept	   to	   several	   other	   reactions	   including	   asymmetric	   Michael	   additions,	   Friedel–Crafts	   alkylations	   as	   well	   as	  
fluorinations	  and	  cyclopropanations.3	  In	  the	  past	  few	  years,	  many	  studies	  have	  aimed	  at	  deciphering	  structural	  rationalizations	  and	  
understanding	  the	  main	  parameters	  that	  control	  the	  stereochemical	  outcome	  of	  a	  given	  DNA-­‐based	  asymmetric	  transformation.4	  
Our	   group	   recently	   joined	   this	   journey	   by	   showing	   that	   dsDNA	   made	   from	   L	   nucleotides	   instead	   of	   the	   natural	   occurring	   D	  
nucleotides	   could	   be	   used	   to	   control	   the	   selectivity	   outcome	   of	   a	   reaction	   and	   thus	   allow	   a	   trivial	   and	   reliable	   access	   to	   both	  
enantiomers.5	   Following	   this	   study,	   we	   also	   reported	   the	   first	   generation	   of	   a	   DNA-­‐based	   catalyst	   bound	   to	   a	   cellulose	  matrix	  
capable	   of	   achieving	   high	   levels	   of	   selectivity	   on	   various	   Cu(II)-­‐catalyzed	   asymmetric	   transformations	   under	   continuous-­‐flow	  
conditions,6a	   as	   well	   as	   new	   anchoring	   strategy	   based	   on	   the	   use	   of	   minor	   groove	   binders.6b	   These	   results	   prompted	   many	  
interrogations	  regarding	  the	  use	  of	  ribonucleic	  acid	  (RNA)	  in	  asymmetric	  metal-­‐catalyzed	  reactions.	  Indeed,	  compared	  to	  dsDNAs,	  
dsRNAs	  exhibit	  certain	  structural	  differences	  such	  as	  a	  wide	  and	  shallow	  minor	  groove	  groove	  associated	  with	  a	  deep	  and	  narrow	  
major	  groove	  with	  11	  base	  pairs	  per	  turn	  versus	  10	  in	  the	  case	  of	  dsDNA	  (Figure	  1).	  In	  addition,	  dsRNAs	  bear	  an	  additional	  2’-­‐OH	  
group	  which	  increases	  their	  thermal	  stability	  by	  locking	  the	  duplex	  into	  a	  compact	  A-­‐form	  helix.7	  	  
	  
Figure	  1.	  Structural	  features	  of	  right-­‐handed	  A-­‐RNA	  and	  B-­‐DNA.	  
	  
While	   it	   is	   well	   known	   that	   naturally	   occurring	   ribozymes,	   which	   are	   large	   folded	   RNA	   plateforms,	   catalyze	   cleavage	   and	  
juncture	  of	  internucleosidic	  linkages	  through	  metal-­‐ion	  interactions,8	  artificial	  ribozymes	  have	  also	  been	  shown	  to	  catalyze	  various	  
synthetic	  transformations	  including	  Diels-­‐Alders,9	  Michael	  additions10	  aldol	  condensations,11	  aminoacylations12	  and	  peptide	  bond-­‐
forming	   reactions.13	  The	  oxidation	  of	   tyramine	   to	   the	  corresponding	   tyramine	  dimer	  using	  a	  cyclic	  dinucleotide	   riboswitch	   fused	  
with	  a	  G-­‐quadruplex	  motif	  has	  also	  been	  recently	  reported.14	  Interestingly	  however,	  except	  for	  a	  few	  examples,9f,15	  most	  of	  these	  in	  
vitro-­‐evolved	  ribozymes	  require	  at	  least	  one	  of	  the	  reactant	  to	  be	  covalently	  attached	  to	  RNA.	  Moreover,	  while	  the	  importance	  of	  
specific	  cations,	  such	  as	  Mg2+	  ions	  in	  the	  case	  of	  Diels-­‐Alderase	  ribozymes,	  has	  been	  demonstrated,16	  Cu2+	  ions	  were	  shown	  to	  be	  
ineffective.9c	   Finally,	   catalytically	   active	   mirror-­‐image	   ribozymes	   (Spiegelzymes),	   which	   are	   resistant	   to	   nuclease	   degradation,17	  
have	  also	  been	  described	  by	  Jäschke18	  and	  Erdmann.19	  
Considering	   these	   points	   and	   following	   our	   previous	   work	   pertaining	   to	   the	   use	   of	   L-­‐dsDNA	   in	   the	   context	   of	   metal-­‐based	  
asymmetric	   catalysis,	  we	  became	   interested	   in	   the	  potential	  use	  of	   short	  and	  defined	  synthetic	   L-­‐oligoribonucleotides	   (L-­‐dsRNA)	  
that	   lack	  a	  catalytically	  active	  binding	  pocket.20	   Indeed,	   in	  contrast	  with	   the	  ribozyme	  approach,	   the	  chiral	   induction	  would	  here	  
result	  from	  a	  non-­‐covalent	  anchorage	  of	  the	  catalytically	  active	  metal	  complex	  into	  the	  chiral	  microenvironment	  provided	  by	  the	  
RNA	  helix.	  We	  report	  here	  the	  results	  of	  our	  endeavor,	  which	  have	  led	  to	  the	  first	  example	  of	  an	  asymmetric	  Fridel-­‐Crafts	  alkylation	  






Table	  1.	  Asymmetric	  Friedel–Crafts	  catalyzed	  by	  L-­‐	  or	  D-­‐RNA	  
 
Our	   study	  was	   initiated	  using	   D-­‐	   and	   L-­‐RNA	   sequences	  
which	  were	  chosen	  on	  the	  basis	  of	  DNA	  sequences	  having	  
previously	   been	   reported	   to	   afford	   high	   levels	   of	  
enantioselectivity.3f,5	   Thus,	   auto-­‐complementary	   L-­‐	   (ORN1)	  
and	   D-­‐	   (ORN2)	   12mer	   5’-­‐(UCAGGGCC	   CUGA)2	   sequences	  
and	   L-­‐	  (ORN3)	   and	   D-­‐	   (ODR4)	   16mer	  
5’-­‐(CAGUCAGUACUGACUG)2	  sequences	  were	  prepared	  and	  
tested.	  The	  RNA	  based	  asymmetric	  Cu(II)-­‐catalyzed	  Friedel–
Crafts	   alkylations	   were	   performed	   by	   reacting	  
α,β-­‐unsaturated	   2-­‐acyl	   imidazole	   1	   (0.6	   μmol)	   with	   5-­‐
methoxyindole	   2	   (3.0	  μmol)	   in	   the	   presence	   of	   4,4’-­‐
dimethyl-­‐2,2’-­‐bipyridine	   (dmbpy,	   36	   mol%),	   Cu(NO3)2	   (30	  
mol%)	  and	  2	  mM	  bp	  of	  RNA	  sequences	  ORN1	  to	  ORN4	  in	  a	  
20	   mM	   MOPS	   buffer	   (pH	   6.5).	   The	   ees	   of	   the	   resulting	  
products	   was	   determined	   by	   chiral	   Supercritical	   Fluid	  
Chromatography	  (SFC)	  analysis.	  The	  results	  are	  summarized	  
in	  Table	  1.	  
Interestingly	   and	   in	   contrast	  with	   the	   results	   obtained	  
with	   dsDNA,	   the	   enantioselectivities	   of	   the	   Friedel–Crafts	  
alkylations	   proved	   to	   be	   highly	   sequence-­‐dependent.	  
Indeed,	   while	   high	   conversions	   were	   obtained	   with	   both	  
12mer	   and	   16mer	   sequences,	   ORN1	   and	   ORN2	   did	   not	  
induce	   any	   enantioselectivity	   (Table	   1,	   entries	   1	   and	   2),	  
while	  ORN3	   and	  ORN4	   afforded	  40%	  ee	  with	  an	   inversion	  
of	   the	   selectivity	   depending	   on	   the	   right-­‐	   or	   left-­‐handed	  
nature	  of	  the	  helix	  (Table	  1,	  entries	  3	  and	  4);	  an	  undeniable	  
evidence	   of	   chirality	   transfer.	   While	   metal	   ions	   cofactors	  
are	  known	  to	  accelerate	  ribozyme	  catalysis21	  a	  controlled	  experiment	  made	  in	  the	  absence	  of	  dmbpy	  led	  to	  full	  conversion	  albeit	  
only	   8%	   ee	   (Table	   1,	   entry	   5).	   This	   confirmed	   the	   importance	   of	   the	   catalytically	   active	  metal-­‐complex	   and	   suggested	   that	   the	  
intrinsic	  nature	  of	   the	  dsRNA(sequence	  and	   length)	  could	   induce	  a	   favourable	  outcome	  through	  a	  different	  mechanism	  than	  the	  
one	  pertaining	  to	  ribozymes	  where	  the	  stereoinduction	  is	  solely	  governed	  by	  the	  shape	  of	  the	  catalytic	  pocket.22	  Hence,	  keeping	  up	  
with	  sequences	  having	  approximately	  50%	  GC	  base	  pairs,	  we	  designed	  and	  synthesized	  ORN5,	  a	  self-­‐complementary	  24mer	  L-­‐RNA	  
and	  ORN6	  a	  68mer	  L-­‐RNA	  hairpin	  (see	  Supporting	  Information).	  Surprisingly,	  ORN5	  only	  led	  to	  a	  racemic	  mixture	  of	  products	  albeit	  
with	  a	  high	  conversion,	  while	  ORN6	  failed	  to	  catalyse	  the	  reaction.	  In	  order	  to	  evaluate	  the	  influence	  of	  the	  sequence,	  six	  additional	  
auto-­‐complementary	  16mer	  L-­‐oligonucleotides	  of	  various	  base	  pair	  compositions	  (ORN7	  =	  	  L-­‐5'-­‐(AAAAAAAAUUUUUUUU)2,	  ORN8	  =	  
L-­‐5'-­‐(GGGGGGGGCCCCCCCC)2,	   ORN9	   =	   L-­‐5'-­‐(AAAAGGGG	   CCCCUUUU)2,	   ORN10	   =	   L-­‐5'-­‐(GGGGUUUUAAAACCCC)2,	   ORN11	  =	  L-­‐5'-­‐
(ACUAUCCGCGGAUAGU)2,	   ORN12	   =	   L-­‐5'-­‐(GCC	   GAUUAUAAUCCGGC)2,	   Table	  1,	   entries	   7-­‐12)	   were	   synthesised	   and	   evaluated;	  
unfortunately,	  none	  of	  them	  led	  to	  any	  improvement	  in	  selectivity.	  Finally,	  increasing	  the	  temperature	  (Table	  1,	  entries	  13-­‐15)	  was	  
detrimental	  as	  a	  complete	  loss	  of	  selectivity	  was	  observed	  when	  running	  the	  reaction	  at	  37	  °C.	  	  	  
	  
Table	  2.	  Influence	  of	  the	  co-­‐solvent	  
In	   an	   attempt	   to	   optimize	   this	   first	   set	   of	   results,	   we	  
decided	   to	   evaluate	   the	   influence	   of	   co-­‐solvents	   and	  
additives.3e,23	   Thus,	   the	   Friedel–Crafts	   alkylation	   of	   1	   with	  
5-­‐methoxyindole	  2	   in	   the	   presence	   of	   dmbpy,	   Cu(NO3)2	   and	  
ORN3	   was	   screened	   with	   a	   variety	   of	   organic	   co-­‐solvents	  
(Table	   2).	   While	   water-­‐miscible	   and	   H-­‐bond	   supporting	  
solvents	  such	  as	  DMSO,	  DMF,	  1,4-­‐dioxane,	  acetone	  and	  EtOH	  
were	   tolerated	  with	   almost	   no	  decrease	   in	   conversion,	   they	  
all	  induced	  a	  clear	  drop	  in	  enantioselectivity	  (Table	  2,	  entries	  
1-­‐5).	  In	  contrast,	  the	  use	  of	  CHCl3,	  which	  is	  not	  miscible	  with	  
water,	   did	   not	   affect	   the	   enantioselective	   outcome	   of	   the	  
reaction,	   but	   led	   to	   a	   decrease	   of	   the	   conversion	   probably	  
due	   to	   the	   higher	   solubility	   of	   the	   reactants	   in	   the	   organic	  
phase	   (Table	   2,	   entry	   6).	   Finally,	   in	   the	   presence	   of	   10%	   of	  
MeCN	  under	  otherwise	   identical	   conditions,	  a	   clear	   increase	  
of	   the	   enantioselectivity	   was	   observed	   (ee	   =	   54%,	   Table	   2,	  
entry	  7)	  confirming	  earlier	  results	  obtained	  with	  DNA.23	  Rising	  
the	  amount	  of	  acetonitrile	  was	  however	  detrimental	  to	  both	  the	  conversion	  and	  the	  ee	  (Table	  2,	  entries	  8-­‐9),	  while	  the	  addition	  of	  
MgCl2	  (10	  mM)	  induced	  a	  reversal	  of	  the	  selectivity	  (Table	  2,	  entry	  10).	  Many	  other	  attempts	  were	  made	  varying	  the	  experimental	  
parameters	   such	  as	   the	  buffer,	   the	  pH	  and	   the	   ligand	   (see	  Supporting	   Information),	  however	  no	  noticeable	   improvements	  were	  
obtained.	  These	  results	  highlight	  the	  importance	  of	  fine-­‐tuning	  both	  the	  sequence	  and	  the	  reaction	  conditions	  in	  order	  to	  achieve	  
high	  levels	  on	  enantioselectivity	  in	  the	  context	  of	  RNA-­‐based	  asymmetric	  catalysis.	  
 
Table	  3.	  Friedel–Crafts	  alkylations	  with	  dsRNA	  
With	  this	  set	  of	  conditions	  in	  hand,24	  we	  next	  undertook	  
to	   explore	   the	   substrate	   scope	   of	   the	   reaction.	   The	   results	  
are	   depicted	   in	   Table	  3.	   Hence,	   in	   sharp	   contrast	   with	  
previously	   reported	   data	   obtained	   with	   dsDNA	   sequences,	  
enones	  containing	  an	  aliphatic	  substituent	  were	  found	  to	  be	  
better	   tolerated	  than	  the	  ones	  bearing	  an	  aromatic	  group.5	  
As	  π-­‐π	   interactions	  between	   the	   substrates	   and	  RNA	  bases	  
may	   induce	   some	   distortion,	   this	   might	   explain	   this	  
observation	  though	  more	  studies	  need	  to	  be	  undertaken	   in	  
order	   to	   fully	   understand	   and	   tame	   this	   new	   type	   of	   bio-­‐
hybrid	  catalytic	  system. 
In	   summary,	   this	   study	   represents	   the	   first	   example	   of	  
an	  asymmetric	  Friedel–Crafts	  alkylation	  using	  an	  RNA-­‐based	  
bio-­‐hybrid	   catalyst.	   Though	   modest,	   the	   enantioselectivies	  
observed	   are	   a	   manifest	   proof	   of	   concept	   that	   small	   RNA	  
sequences	   can	   be	   used	   to	   control	   the	   enantioselctive	  
outcome	   of	   a	   given	   reaction.	   These	   results	   show	  
tremendous	   promise	   and	   underline	   the	   many	   different	  
requirements	   regarding	   RNA	   sequences	   and	   folding	  
compared	   to	   their	   ribozymes	   analogues.	   A	   precise	  
understanding	   of	   the	   governing	   factors	   is	   now	   needed	   to	  
rationalize	   and	   tune	   the	   RNA	   chiral	   environment	   into	   a	  
competitive	  chiral	  scaffold.	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2 >99 (−) 40
3 >99 (−) 30
4 >99 (−) 38
5 93 (−) 10
Conditions: 2 mM base pair solution of RNA in a 20 mM MOPS solution (400 µL; pH 6.5), 0.3 mM of 
Cu(dmbpy)(NO3)2 in a 20 mM MOPS solution (200 mL), 0.5 M solution of enone in CH3CN (1.2 µL), 
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24	   General	   procedure	   for	   the	  RNA-­‐catalysed	   Friedel–Crafts	   alkylation.	  To	  a	  3	  mM	  base	  pair	   solution	  of	   the	  desired	  RNA	  sequence	   in	  a	  
20	  mM	  MOPS	   buffer	   (400	   μL)	   was	   added	   a	   0.9	  mM	   solution	   of	   [Cu(dmbpy)(NO3)2]	   in	   a	   20	  mM	  MOPS	   buffer	   (200	  μL).	   The	   resulting	  
solution	   (2	  mM	  base	   pair,	   600	   μL)	  was	   cooled	   to	   5	  °C.	   To	   the	   cold	  mixture	  was	   added	   a	   0.5	  M	   solution	   of	   enone	   in	  MeCN	   (1.2	  μL),	  
followed	  by	  a	  2.5	  M	  solution	  of	  substituted	  indole	  in	  MeCN	  (1.2	  μL).	  The	  reaction	  was	  mixed	  by	  inversion	  at	  5	  °C	  in	  a	  cold	  room.	  After	  
1	  d,	  the	  mixture	  was	  warmed	  to	  rt	  and	  extracted	  with	  Et2O	  (3	  x	  2	  mL).	  The	  combined	  organic	  layers	  were	  washed	  with	  brine	  (2	  mL),	  dried	  
over	   Na2SO4,	   filtered	   through	   a	   plug	   of	   silica	   gel	   and	   concentrated	   under	   reduced	   pressure,	   to	   give	   the	   crude	   product	   which	   was	  
subjected	  to	  SFC	  analysis	  without	  further	  purification.	  
